ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 6

Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

October 29, 2024

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center, Christine Bestvina, MD, University of Chicago, Hatim Husain, MD, Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center, Julia K. Rotow, MD

This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.

EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP. 3: ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP. 4: Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP. 5: Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

Now Viewing

EP. 6: Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP. 7: Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP. 8: Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

EP. 9: Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP. 10: Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP. 11: Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP. 12: Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Video content above is prompted by the following:

Please briefly discuss the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted available, targeted therapies.
What are the clinical benefits of a targeted ADC approach vs chemotherapy for heavily pretreated advanced/metastatic NSCLC?